[go: up one dir, main page]

MX2021000071A - Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. - Google Patents

Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.

Info

Publication number
MX2021000071A
MX2021000071A MX2021000071A MX2021000071A MX2021000071A MX 2021000071 A MX2021000071 A MX 2021000071A MX 2021000071 A MX2021000071 A MX 2021000071A MX 2021000071 A MX2021000071 A MX 2021000071A MX 2021000071 A MX2021000071 A MX 2021000071A
Authority
MX
Mexico
Prior art keywords
pridopidine
subject
cognitive function
disease
treating alzheimer
Prior art date
Application number
MX2021000071A
Other languages
English (en)
Inventor
Michael Hayden
Merav Bassan
Michal Geva
Ilya Bezprozvanny
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of MX2021000071A publication Critical patent/MX2021000071A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Esta invención proporciona un método para mejorar la función cognitiva en un sujeto, que comprende administrar periódicamente al sujeto una cantidad de pridopidina o una sal farmacéuticamente aceptable de la misma efectiva para mejorar la función cognitiva en el sujeto. La invención también proporciona un método para tratar un sujeto que padece de enfermedad de Alzheimer, que comprende administrar periódicamente al sujeto una composición farmacéutica que comprende una cantidad de pridopidina o una sal farmacéuticamente aceptable de la misma efectiva para tratar al sujeto.
MX2021000071A 2015-02-25 2017-08-25 Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. MX2021000071A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562120771P 2015-02-25 2015-02-25
US201562186221P 2015-06-29 2015-06-29

Publications (1)

Publication Number Publication Date
MX2021000071A true MX2021000071A (es) 2021-03-25

Family

ID=56689699

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017010982A MX378579B (es) 2015-02-25 2016-02-24 Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2021000071A MX2021000071A (es) 2015-02-25 2017-08-25 Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017010982A MX378579B (es) 2015-02-25 2016-02-24 Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.

Country Status (13)

Country Link
US (1) US10603311B2 (es)
EP (4) EP3261721B1 (es)
JP (2) JP6887952B2 (es)
AU (2) AU2016222796B2 (es)
CA (1) CA2977264C (es)
DK (1) DK3261721T3 (es)
ES (1) ES2930628T3 (es)
HU (1) HUE060353T2 (es)
IL (2) IL254030B (es)
MX (2) MX378579B (es)
PL (1) PL3261721T3 (es)
TW (1) TW201639570A (es)
WO (1) WO2016138130A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
UY34503A (es) 2011-12-08 2013-07-31 Ivax Int Gmbh ?sal de bromhidrato de pridopidina?
PE20170302A1 (es) 2013-06-21 2017-03-31 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) * 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
EP3261721B1 (en) 2015-02-25 2022-09-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve memory
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
HUE066769T2 (hu) 2016-02-24 2024-09-28 Prilenia Neurotherapeutics Ltd Neurodegeneratív szembetegség kezelése pridopidinnal
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
CN115671103A (zh) * 2016-08-24 2023-02-03 普瑞尼亚神经治疗有限公司 普利多匹定用于治疗功能下降的用途
US20210093622A1 (en) * 2016-09-15 2021-04-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of anxiety and depression
AU2017326436A1 (en) * 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
HUE058314T2 (hu) * 2016-09-16 2022-07-28 Prilenia Neurotherapeutics Ltd Pridopidin alkalmazása Rett-szindróma kezelésére
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
BR112019015000A2 (pt) * 2017-01-20 2020-04-07 Agency Science Tech & Res uso de pridopidina para o tratamento da síndrome do x frágil
CA3072882C (en) * 2017-08-14 2023-03-21 Prilenia Neurotherapeutics Ltd. Method of treating amyotrophic lateral sclerosis with pridopidine
WO2019046568A1 (en) 2017-08-30 2019-03-07 Teva Pharmaceuticals International Gmbh DOSAGE FORMS WITH HIGH CONCENTRATION OF PRIDOPIDINE
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
EP3678664A1 (en) 2017-09-08 2020-07-15 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
JP7585561B2 (ja) * 2019-02-04 2024-11-19 プリレニア ニューロセラピューティクス リミテッド パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
WO2020188558A1 (en) * 2019-03-15 2020-09-24 Prilenia Neurotherapeutics Ltd. Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE201669T1 (de) 1991-04-17 2001-06-15 Upjohn Co Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
SE9702716D0 (sv) * 1997-07-15 1997-07-15 Ross Nicholas Waters Substituted phenylazacycloalkanes in the treatment of cognitive disorders
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
EP2357474A1 (en) * 2004-02-20 2011-08-17 Dainippon Sumitomo Pharma Co., Ltd. Lurasidone for use in the treatment of memory or learning dysfunction by schizophrenia
CN101056854B (zh) 2004-10-13 2013-06-05 Nsab神经研究瑞典公司分公司 合成4-(3-甲磺酰基苯基)-1-n-丙基-哌啶的方法
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
SI2146961T1 (sl) 2007-04-12 2014-08-29 IVAX International GmbH N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkov
US9084742B2 (en) * 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
DK2421519T3 (en) 2009-04-23 2017-02-06 Univ Zuerich NMDA RECEPTOR BLOCKERS FOR THE TREATMENT OF SEAL CELL ANAEMS
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US8849866B2 (en) 2010-02-22 2014-09-30 Infosys Limited Method and computer program product for creating ordered data structure
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
US9000047B2 (en) 2010-05-24 2015-04-07 Farmalider, S.A. Compound inhibiting activation of the enzyme Erk 1/2 to be used in the treatment of neurodegenerative illnesses
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
WO2013034622A1 (en) 2011-09-07 2013-03-14 Neurosearch A/S Polymorphic form of pridopidine hydrochloride
UY34503A (es) * 2011-12-08 2013-07-31 Ivax Int Gmbh ?sal de bromhidrato de pridopidina?
US20130267552A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
WO2014052935A2 (en) * 2012-09-27 2014-04-03 Teva Pharmaceutical Industries Ltd. Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
IN2015DN03219A (es) 2012-09-27 2015-10-02 Teva Pharma
WO2014195322A1 (en) 2013-06-04 2014-12-11 Acturum Life Science AB Triazole compounds and their use as gamma secretase modulators
PE20170302A1 (es) 2013-06-21 2017-03-31 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
CA2937243C (en) 2014-01-22 2023-07-18 Teva Pharmaceuticals International Gmbh Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP3261721B1 (en) 2015-02-25 2022-09-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve memory
US20170020854A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
CN115671103A (zh) 2016-08-24 2023-02-03 普瑞尼亚神经治疗有限公司 普利多匹定用于治疗功能下降的用途
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途

Also Published As

Publication number Publication date
US20160243098A1 (en) 2016-08-25
TW201639570A (zh) 2016-11-16
EP3854785A1 (en) 2021-07-28
AU2021201583B2 (en) 2022-04-07
IL286888A (en) 2021-10-31
JP2021073206A (ja) 2021-05-13
CA2977264C (en) 2021-12-07
AU2021201583A1 (en) 2021-04-01
CA2977264A1 (en) 2016-09-01
DK3261721T3 (da) 2022-11-28
MX378579B (es) 2025-03-11
IL254030A0 (en) 2017-10-31
US10603311B2 (en) 2020-03-31
EP3261721A4 (en) 2018-08-08
PL3261721T3 (pl) 2022-12-27
EP3261721A1 (en) 2018-01-03
AU2016222796B2 (en) 2021-07-15
HUE060353T2 (hu) 2023-02-28
EP4282479A2 (en) 2023-11-29
MX2017010982A (es) 2017-11-20
JP6887952B2 (ja) 2021-06-16
WO2016138130A1 (en) 2016-09-01
AU2016222796A1 (en) 2017-10-05
IL254030B (en) 2022-01-01
EP3261721B1 (en) 2022-09-14
EP4282479A3 (en) 2024-02-21
ES2930628T3 (es) 2022-12-20
EP3590512A1 (en) 2020-01-08
JP7210620B2 (ja) 2023-01-23
JP2018506569A (ja) 2018-03-08

Similar Documents

Publication Publication Date Title
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX394909B (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2021002321A (es) Nuevos metodos.
PH12017500493A1 (en) Combination therapy
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
IN2015DN03219A (es)
MX337614B (es) Tratamiento de lupus nefritis usando laquinimod.
PH12012501741A1 (en) Treatment of lupus arthritis using laquinimod
PH12012501740A1 (en) Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
MX2015012322A (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MD20160007A2 (ro) Inhibitori ai RORC2 şi metode de utilizare a acestora
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
EA201691567A1 (ru) Способы лечения легких травм головного мозга
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MX2016008968A (es) Compuestos organicos.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MY205171A (en) Methods of treatment of hypertriglyceridemia
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2019004200A (es) Terapia de combinacion.
GB201115977D0 (en) Neurodevelopmental disorders
MX2018004777A (es) Compuestos oxa-diazaspiro que tienen actividad contra el dolor.
MX2014013491A (es) Metodos para mantener, tratar o mejorar la funcion cognitiva.